Drugs that lack single-agent activity: are they worth pursuing in combination?

    loading  Checking for direct PDF access through Ovid

Abstract

Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.

    loading  Loading Related Articles